Free Trial
→ $0. Later: $29.97. (From Profits Run) (Ad)tc pixel
NASDAQ:LUCD

Lucid Diagnostics Q3 2026 Earnings Date & Estimates

Lucid Diagnostics logo
$0.42 +0.02 (+4.90%)
Closing price 11/9/2026 04:00 PM Eastern
Extended Trading
$0.42 +0.00 (+0.12%)
As of 11/9/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Lucid Diagnostics is estimated to report Q3 2026 earnings on Thursday, November 12, 2026, before market opens. The conference call is scheduled for 8:30 AM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Conference Call
8:30 AM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Lucid Diagnostics in Q3 2026

Lucid Diagnostics is expected to post earnings of -$0.06 per share on revenue of $1.63 million. In the same quarter a year earlier Lucid Diagnostics reported -$0.10 per share on revenue of $1.21 million. Lucid Diagnostics last reported on August 12, 2026, posting -$0.06 per share and missing the -$0.0567 consensus estimate. Lucid Diagnostics has beaten the consensus EPS estimate in 0 of its last 4 quarters.

Consensus Estimates

Consensus EPS
-$0.06
Expected Revenue
$1.63 million
Prior-Year EPS
-$0.10
Prior-Year Revenue
$1.21 million
Expected Revenue Growth
+34.9%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.06 (Missed by -$0.0033)
Last Quarter Revenue
$1.47 million
EPS Beat Rate
0 of last 4 quarters

Prepare for the Q3 2026 Call

Lucid Diagnostics Q3 2026 Earnings FAQ

Lucid Diagnostics (NASDAQ:LUCD) is estimated to report Q3 2026 earnings on Thursday, November 12, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

Lucid Diagnostics' Q3 2026 earnings conference call is scheduled for Thursday, November 12, 2026 at 8:30 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Lucid Diagnostics to post earnings of -$0.06 per share for Q3 2026.

The consensus revenue estimate for Lucid Diagnostics is $1.63 million for Q3 2026.

Lucid Diagnostics Earnings Headlines

Lucid Diagnostics Inc. (LUCD) - What Are Investment Firms Saying About This Stock?
November 9 at 3:15 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31187493
Lucid Diagnostics Recognized as a GenomeWeb Best Place to Work for Second Consecutive Year
November 5, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/lucid-diagnostics-recognized-as-a-genomeweb-best-place-to-work-for-second-consecutive-year-302930663.html
Many investors are about to lose everything
Twenty five years ago, this analyst predicted the fiber optic boom and called Amazon before it became a household name. Now he says a similar shift is unfolding in AI infrastructure. Hundreds of billions are pouring into AI data centers, but he warns the builders could get crushed by their own costs while one overlooked sector absorbs the spending.tc pixel
 |  Porter & Company (Ad)
Lucid Diagnostics (LUCD) Projected to Release Earnings on Thursday
November 5, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31179087
Lucid Diagnostics Inc. Announces Publication of Landmark 12,000-Patient Real-World Esoguard Study
November 4, 2026  |  marketscreener.comM
Lucid Diagnostics to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
November 4, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/lucid-diagnostics-to-participate-in-the-canaccord-genuity-medtech-diagnostics-and-digital-health--services-forum-302928934.html
See More Lucid Diagnostics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Lucid Diagnostics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Lucid Diagnostics and other key companies, straight to your email.

About Lucid Diagnostics

Lucid Diagnostics (NASDAQ:LUCD) (NASDAQ: LUCD) is a medical diagnostics company focused on improving the detection of esophageal disease. The company develops and commercializes diagnostic technologies intended to identify patients at elevated risk of esophageal cancer, particularly those with gastroesophageal reflux disease (GERD).

Lucid’s principal products include EsoGuard, a laboratory-developed DNA test that analyzes cells collected from the esophagus for molecular changes associated with Barrett’s esophagus and esophageal cancer risk, and EsoCheck, a swallowable, balloon-based device designed to collect cells from the esophageal lining. The products are intended to support noninvasive or minimally invasive screening and help identify patients who may require further evaluation.

Founded in 2018, Lucid Diagnostics is headquartered in New York and serves the U.S. market through healthcare providers, medical practices and other clinical channels. The company was co-founded by Lishan Aklog, M.D., who has served in leadership roles including chairman and chief executive officer. Lucid Diagnostics operates as a subsidiary of PAVmed Inc.

View Lucid Diagnostics Profile
Earnings Tools